Skip to main content
. 2021 Apr 3;11(12):5955–5969. doi: 10.7150/thno.58164

Figure 4.

Figure 4

CA4-NPs + DC101 improved the therapeutic efficacy of anti-PD-1. (A) Schematic representation of the drug treatment strategy. (B, C, D). Tumor growth curves (B, n = 10), body weight changes (C, n = 10), and survival curves (D, n = 10) of the eight groups following drug treatment. (E) IHC staining of Ki67 and H&E for tumors in the Group 1, Group 4, Group 5, and Group 8 on day 11. V, viable region of the tumors; N, necrotic region of the tumors. (F) Quantitative analysis of the Ki67+ area (Ki67+ area/field) using the Image J software (n = 3). (G) Quantitative analysis of the necrotic area (necrotic area/field) using the Image J software (n = 3). (H) Representative flow cytometry plots for intratumoral CD4+ T (CD3+CD4+) cells and CD8+ T (CD3+CD8+) cells in the Group 1, Group 4, Group 5, and Group 8 on day 11. (I, J) Quantification of intratumoral CD4+ T cells (I, n = 6) and CD8+ T cells (J, n = 6) detected by flow cytometry. (K, L) ELISA for evaluating intratumoral IFN-γ (K, n = 3) and TNF-α (L, n = 3) levels in the Group 1, Group 4, Group 5, and Group 8 on day 11. Data are presented as mean ± SD (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, not significant). Note: PBS (Group 1); CA4-NPs (Group 2); DC101 (Group 3); anti-PD-1 (Group 4); CA4-NPs + DC101 (Group 5); CA4NPs + anti-PD-1 (Group 6); DC101 + anti-PD-1 (Group 7); and CA4-NPs + DC101 + anti-PD-1 (Group 8).